Methyl-methanesulfonate sensitivity 19 expression is associated with metastasis and chemoradiotherapy response in esophageal cancer

Table 2 Associations of MMS19 expression with clinicopathologic features of esophageal squamous cell carcinoma

Characteristic	Cases (n)	Cytoplasmic MMS19			Nuclear MMS19
		High	Low	P value	High	Low	P value
Total	103	65	38		36	67
Sex
Male	84	55	29	0.295	32	52	0.159
Female	19	10	9		4	15
Age (yr)
< 55	33	18	15	0.216	14	19	0.275
≥ 55	70	47	23		22	48
Site
Upper thoracic	10	7	3	0.686	2	8	0.508
Middle thoracic	47	31	16		16	31
Lower thoracic	46	27	19		18	28
Differentiation
Well	20	13	7	0.785	6	14	0.871
Moderate	52	34	18		19	33
Poor	31	18	13		11	20
TNM stage
I + II	27	14	13	0.158	8	19	0.500
III + IV	76	51	25		28	48
Invasion depth
T1 + T2	25	17	8	0.560	7	18	0.402
T3 + T4	78	48	30		29	49
LNM
No	12	2	10	< 0.001	4	8	0.900
Yes	91	63	28		32	59
DM
No	85	48	37	0.002	32	53	0.212
Yes	18	17	1		4	14

DM: Distant metastases; ESCC: Esophageal squamous cell carcinoma; High: Including composite score of 6, 8, 9 and 12; LNM: Lymph node metastases; Low: Including composite score of 0, 1, 2, 3 and 4; MMS19: methyl-methanesulfonate sensitivity 19.